# Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

> **NCT04943627** · PHASE3 · WITHDRAWN · sponsor: **Agenus Inc.**

## Conditions studied

- Advanced Cancer
- Metastatic Cervical Cancer

## Interventions

- **DRUG:** Balstilimab (BAL)
- **DRUG:** Topotecan
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04943627
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-02
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic Business Decision
- **Last updated:** 2022-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943627, "Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04943627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*